论文部分内容阅读
干细胞治疗代表生物冶疗进入到了一个崭新的时代。间充质干细胞是存在于胚胎或成体组织中来源于中胚层具有多向分化潜能的干细胞。由于成体间充质干细胞的质量与数量自身缺陷,使之应用受到了很大限制。Wharton’s jelly组织,是起始于胚胎发育第13天的胚外中胚层组织。使用基因微阵列分析及功能分析,首次发现Wharton’s jelly源间充质干细胞(Wharton’s jelly derived mesenchymal stem cells,WJMSCs)高表达胚胎早期干性基因及心肌细胞分化早期特异转录因子,可分化心肌细胞等多种细胞。进而,应用临床级WJMSCs经冠状动脉移植治疗ST抬高型急性心肌梗死患者的随机双盲临床试验,首次证明WJMSCs可明显改善心肌活力及心脏功能。因此,WJMSCs具有极其重要益处;无伦理涉及,有强的分化潜能,无致瘤性;加之,WJMSCs可作为产品,在任何时候病情需要时立即应用。为此,WJMSCs作为真正意义上的干细胞族,将最有希望成为具有应用前景的于细胞生物药。
Stem cell therapy represents a new era for bio-therapy. Mesenchymal stem cells are stem cells that exist in the embryonic or adult tissues and have multi-directional differentiation potential derived from the mesoderm. Due to the quality and quantity of adult mesenchymal stem cells themselves defects, the application has been greatly restricted. Wharton’s jelly tissue, which is an extraembryonic mesoderm tissue that begins on day 13 of embryonic development. Using gene microarray analysis and functional analysis, we found for the first time that Wharton’s jelly derived mesenchymal stem cells (WJMSCs) express high levels of early embryonic genes and early cardiomyocytes differentiation-specific transcription factors and differentiable cardiomyocytes Seed cells. Furthermore, the randomized double-blind clinical trial of clinical WJMSCs transcatheter arterial grafting in patients with ST-elevation acute myocardial infarction demonstrated for the first time that WJMSCs can significantly improve myocardial viability and cardiac function. Therefore, WJMSCs have extremely important benefits; unethical involvement, strong differentiation potential and no tumorigenicity; furthermore, WJMSCs can be used as a product and applied immediately whenever needed. To this end, WJMSCs as the real stem cell family, will be the most promising cell biomedicine with promising.